Oxford Vaccine "Could Be Realistic Solution" To Covid: ICMR

Thursday, 12 November 2020Newsdesk

The Pune-based Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) on Thursday announced the completion of enrolment of phase-3 clinical trials for potential COVID-19 vaccine Covishield in India. The ICMR and SII have collaborated for the clinical development of Covovax developed by Novavax, US and upscaled by SII, a statement said.

New Delhi, 12 November 2020

"The partnership is a stellar example of private-public institutes collaborating to mitigate the dire consequences of the pandemic outbreak," the ICMR said in the statement. As per news report of NDTV, while the ICMR has funded the clinical trial site fees, SII has funded other expenses for Covishield.

Source -NDTV